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Mesenchymal stem/stromal cells (MSCs) are multipotent progenitors that are derived from most adult tissue as 
well as cord blood and placenta. MSCs are defined by their adherent nature, ability to propagate in culture and 
capacity to differentiate into bone, fat, and cartilage. However, many studies have shown that MSCs, derived 
from different tissues, differ both in their in situ and in vitro phenotypes. Despite abundance of MSCs studies, 
little is known about the molecular events that control their tissue specific nature. Two recent studies comparing 
MSCs derived from different tissues have now found clues to the molecular mechanisms that control the tissue 
specific nature of these cells. In the first, the superior genomic stability of adipose derived MSCs (ASCs), 
compared to bone marrow (BM) MSCs, was explained by reduced H19 long non-coding RNA expression, and 
increased p53 activity of ASCs. In the second, a comparison of abdominal and subcutaneous ASCs revealed poor 
propagation, differentiation and migration capacities of abdominal ASCs that is explained by their increased 
tendency to over-accumulate reactive oxygen species (ROS) in culture. ROS over production in abdominal ASCs 
was shown to be controlled by the NADPH oxidase NOX1. The unique features of MSCs derived from different 
tissues suggest a tissue specific molecular signature arising from the tissue of origin that is retained during 
culture. The implications of this phenomenon on our understanding of the role and function of MSCs in situ as 
well as on their clinical utilization, is discussed. 
To cite this article: Ofer Shoshani, et al. The tissue specific nature of mesenchymal stem/stromal cells: Gaining better 
understanding for improved clinical outcomes. RNA Dis 2015; 2: e780. doi: 10.14800/rd.780. 
What defines a Mesenchymal stem/stromal cells (MSCs)? 
Mesenchymal cells from bone marrow (BM) and adipose 
tissues were isolated and propagated under tissue culture 
conditions since the 1960's [1-3]. The concept of multipotent 
mesenchymal cells that are responsible for the repair and 
turnover of adult tissue was later suggested and the term 
mesenchymal stem cells (MSCs) was coined to indicate their 
multipotent differentiation potential. Based on the MSC 
concept, a new field of cell based regenerative medicine has 
emerged [4]. MSCs have since been isolated from various 
adult tissues, as well as from cord blood and placenta [5], and 
their clinical potential as a regenerative or 
immunosuppressive tool was appreciated leading to a 
dramatic increase in MSCs clinical and pre-clinical research 
[6]. Given that an important clinical requirement for any 
pharmaceutical treatment, including cell therapy, is it’s 
uniform and reproducible nature, a set of unifying 
characteristics for all MSCs was suggested at 2006 [7]. The 
characteristics in these guidelines were based on the common 
properties of MSCs that include their plastic adherent nature, 
their multipotent differentiation ability and a set of positive 
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surface markers that appear on all MSCs but are expressed 
also on other cell types.  
Are in situ MSC progenitors and cultured MSCs that 
arise from different tissues the same?  
In spite of the common properties of MSCs that were 
listed in the International Society for Cellular Therapy 
(ISCT) guidelines, significant differences between 
mesenchymal stem/stromal cells that were derived from 
different tissues were observed since their identification. 
Differences in the relative ease of propagation and 
differentiation spectrum of mesenchymal cells that were 
isolated from perirenal and epididymal fat were observed 
[8-10]. Following these early studies many subsequent ones 
have now reported differences in the propagation and 
differentiation abilities of MSCs that were isolated from 
different tissues, as was recently reviewed in [11]. The tissue 
specific nature of MSCs became most evident during the 
continuous search for a unique MSC surface marker that 
would allow their isolation and identification in situ. As was 
recently reviewed by LV et al  [12] most of the suggested 
markers (Stro-1, CD27, SSEA-4 etc.) are heterogeneously 
expressed on MSCs derived from different tissues. This 
tissue specificity is also observed in the case of CD34, which 
is uniquely expressed in adipose derived MSCs (ASCs). 
CD34 expression on ASCs was reported to be transient (in 
early passages) or continuous (20 weeks) [13, 14]. The in situ 
origin of MSCs is also a matter of debate. The perivascular 
niche was proposed as an origin for MSCs of various tissues 
[15], but it was recently shown that CD34 positive ASCs 
(CD34+ cells were demonstrated to be responsible for the 
CFU-F capabilities of stromal fat cells) do not localize in 
proximity to blood vessels and are therefore not of 
perivascular origin [16]. Craniofacial-bone MSCs that were 
able to give rise to all craniofacial bones in the adult and 
were activated during injury repair were also not associated 
with vasculature [17].  
Can the tissue specific signature of mesenchymal cells be 
maintained despite the culture adaptation of MSCs? 
The tissue specific phenotype of MSCs is most likely 
controlled by a molecular signature that originates from their 
in situ environmental niche. MSCs undergo a drastic 
transformation/selection process during their culture 
cultivation starting from a heterogeneous population to 
become a relatively homogenous one in which the majority 
of cells express what is termed mesenchymal stem cells 
markers, such as CD90, CD29, CD105, CD73, among others. 
This homogenous expression is in sharp contrast to the 
heterogeneous marker expression in the original stromal 
vascular fraction (SVF)/BM populations that express CD45, 
CD34, CD31 as well as the mesenchymal markers but to a 
much lower extent. Given the drastic transition of MSCs 
during culture it is unclear whether the tissue specific 
signature would be maintained under culture conditions. 
Alternatively, the proposed signature may still be evident in 
the more heterogeneous but early progenitor population. In 
two recently published studies we therefore compared BM 
marrow derived MSCs to adipose derived MSCs (ASCs) [18] 
and abdominal ASCs (aASCs) to subcutaneous ASCs 
(scASCs) [19]. It was found that ASCs are more genetically 
stable than BM MSCs and demonstrate a more homogenous 
nature in their response to changing or stressful conditions. 
ASCs from abdominal and subcutaneous sources were found 
to differ in their propagation, fat differentiation and 
migration potentials. All of these tissue specific traits were 
reproducible in many repeats of MSC preparations and were 
demonstrated in cultured MSCs that were propagated under 
identical conditions. Importantly, it was shown that the 
phenotypic differences between MSCs from different tissues 
could be explained by the differential expression of specific 
genes that controlled their phenotype. It thus seems that the 
tissue specific signature of MSCs can be studied in cultured 
MSCs and not only in early progenitors immediately 
following their isolation.  
Why are ASCs more gnomically stable and less 
tumorigenic than BM MSCs?  
In a recent work [20] a clear correlation between the 
expression levels of H19, a long non-coding RNA, which 
also serves as a precursor for mir675, and the tendency of 
mouse BM MSCs to become polyploid in culture was 
demonstrated. More specifically, it was observed that BM 
MSCs rarely maintain a diploid genome in culture, as most 
populations become polyploid. In BM MSCs, polyploidy 
appeared to be a more stable state than diploidy as diploid 
BM MSCs were significantly more tumorigenic following 
subcutaneous administration, and expressed much higher 
levels of H19. The correlation between H19 expression and 
the tendency of BM MSCs to become polyploid was further 
substantiated in another recent publication that compared the 
genomic stability of BM MSCs to that of ASCs [18]. 
Altogether, it was found that 76% (13 out of 17 cell 
preparations) of mouse BM MSCs preparations, 
demonstrated a polyploid phenotype compared to only 9% 
polyploidy (3 out of 32 cell preparations)  of ASCs. The 
reduced tendency of ASCs to become polyploid was 
demonstrated under various conditions that included hypoxic 
(3% oxygen) and normoxic (21% oxygen) conditions and a 
range of culture media. Importantly, under both hypoxic and 
normoxic conditions diploid ASCs demonstrated a 
dramatically reduced H19 expression compared to polyploid 
BM MSCs (43 and 59 fold respectively) further supporting 
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the idea that lower H19 expression is correlated with 
increased genomic stability and reduced tumorigenicity. The 
exact role of H19 in the maintenance of genomic stability 
and in the process of cellular transformation is unclear. 
However, previous studies showed that increased H19 
expression levels can serve as a marker for tumor cells [21-24], 
which lead to its use as a clinical bio-marker in the treatment 
of various cancer types [25]. In the recent work [20] it was 
unveiled that H19 expression is higher in proliferating cells, 
and is also elevated dramatically in cells exposed to UV 
light. It is therefore possible that H19 expression facilitates 
the ability of normal cells to adjust to stressful conditions. In 
cancerous cells, however, unregulated expression of H19 
promotes uncontrolled cell proliferation. The PI3K/Akt 
pathway is a critical regulator of the transition of diploid 
hepatocytes to a tetraploid state after weaning [26], and also 
plays a role in epithelial-mesenchymal transition (EMT), 
tumor metastasis and H19 expression [23]. PI3K/Akt may thus 
take part in both H19 regulation and the transition of BM 
MSCs from a diploid to a tetraploid state.  
Is p53 activity involved in ASCs increased genomic 
stability?  
It was previously proposed that tetraploidy leads to cell 
transformation and tumor formation and is therefore 
prevented by the tumor suppressor p53 [27]. The recent study 
[20] suggested that in some instances the opposite is true, 
namely tetraploidy is necessary for p53 wild type cells to 
remain non-tumorigenic. It was additionally found that the 
basal p53 activity, evident by the RNA expression of various 
p53 target genes, was significantly higher in ASCs compared 
to BM MSCs [18]. Interestingly, three different DNA damage 
stresses (UV eradiation, oxidative stress by H202 and 
doxorubicin) all resulted in a significant p53 activation in 
both tetraploid BM MSCs and in ASCs demonstrating the 
presence of a wild type p53 in these cells. It thus seems that 
the increased basal p53 activity together with the reduced 
H19 expression contributes to the superior ability of ASCs to 
remain diploid [18]. Importantly, a non-transformed state is 
achieved in different ways in ASCs and BM MSCs, as the 
former maintain a diploid genome whereas the latter become 
tetraploid. 
Do ASCs, derived from different adipose tissues, differ in 
fundamental properties such as their propagation, fat 
differentiation and migration potential?  
The tissue specific nature of MSCs was further 
demonstrated in a comparison of aASCs and scASCs which 
revealed superior propagation, fat differentiation and 
migration capacities of the latter [19]. The poor expansion 
ability of aASCs, which was translated into cytostasis at 
early passages, was found to occur because of increased 
apoptosis. Importantly, cytostasis and apoptosis were 
correlated with ROS accumulation and increased NOX1 
expression in aASCs that was not observed in scASCs. 
Inhibition of NOX1 by a specific inhibitor (ML171) reduced 
ROS accumulation and apoptosis of aASCs and allowed their 
long term expansion, substantiating the importance of NOX1 
activity in aASCs cytostasis. NOX1 specific inhibition was 
able also to improve aASCs fat differentiation and migration 
capabilities reaffirming NOX1 role in aASCs tissue specific 
phenotype. As was previously described, MSCs undergo 
adaptation to tissue culture conditions following their 
isolation. One of this adaptations is the adjustment of ASCs to 
atmospheric oxygen level (21% oxygen) which is much 
higher than physiological oxygen levels within the tissue 
(3-6% oxygen in fat) [28]. The findings presented in the recent 
study indicate that NOX1 induced ROS accumulation resulted 
from the adaptation of aASCs to atmospheric oxygen 
conditions since aASCs that were cultured at 3% oxygen did 
not display increased NOX1 and ROS levels and were able to 
undergo long-term expansion in culture. In conclusion, ASCs 
derived from different tissues seem to harbor a tissue specific 
molecular signature, displayed by a discriminant gene 
expression profile that leads to tissue specific phenotypes. 
Does the MSC in vitro phenotype reflect the physiological 
role of MSC progenitors within the tissue?  
The function of MSCs in vivo is largely unknown, however, 
they are believed to play an important role in tissue 
homeostasis, protection and regeneration. In order to survive 
under and react to stressful and rapidly changing conditions, 
MSCs must retain a plastic nature. One of the manifestation of 
the plastic nature of MSCs is the heterogeneous phenotypes 
that are displayed by distinct BM MSC preparations in culture 
[29]. Indeed, in a study examining the reaction of MSCs to 
different toll-like receptor (TLR) ligands, it was found that 
distinct MSC preparations respond with great variability to 
different types of treatments [30]. A different aspect of the 
plasticity of MSCs was discovered in a recent study showing 
that a single cell isolation of MSCs triggered a spontaneous 
reprogramming event which allowed the cells to acquire new 
differentiation potentials [31]. This reprogramming event, 
however, occurred only in normoxic conditions, and not in 
cells cultured in 3% oxygen. Thus, it is possible that within the 
niche, MSCs are protected from changing oxygen levels, and 
other environmental cues (e.g. TLR ligands) and thus retain a 
stable phenotype. Once they migrate out of the niche towards 
damaged tissue sites and are exposed to new environments, 
their plastic nature allows them to survive and take part in 
recovery processes. In sharp contrast to BM MSCs, ASCs 
appear to be more homogenous, however, oxygen availability 
still plays an important role in their behavior [19]. 
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Another indication for the possible in vivo functions of 
MSCs comes from the recent findings which demonstrate the 
tendency of aASCs to accumulate ROS in culture [19]. The 
role of increased ROS accumulation in adipose tissue during 
obesity and its involvement in the development of the 
metabolic syndrome is well established [32-35]. The 
involvement of NOX enzymes in ROS production in adipose 
tissue during obesity has also been demonstrated [33, 34, 36-38]. 
The development of the metabolic syndrome is accompanied 
by accumulation of pro-inflammatory cytokines. Importantly, 
obesity is attributed to abdominal/visceral fat rather than 
subcutaneous fat [39]. In light of the above, our recent 
findings regarding the increased tendency of aASCs and not 
of scASCs to express NOX enzymes, accumulate reactive 
oxygen species, accumulate pro-inflammatory cytokines and 
undergo extensive apoptosis, may provide novel mechanistic 
clues to the involvement of ASCs progenitors in the 
development of the metabolic syndrome [19]. This notion is 
further substantiated by the claim that MSCs are derived 
from a perivascular cells [15] and by the many evidences that 
connect ROS production by vascular cells to the 
development of obesity: NOX1 was shown to be expressed 
in vascular smooth muscle cells, and its mRNA expression 
was up-regulated and activated by vascular pathological 
stimuli [40, 41]. Overexpressing of ph22phox (a subunit of the 
NOX complex) in vascular cells was recently shown to play 
a causal role in development of the metabolic syndrome 
indicating that overexpression of ROS in vascular cells may 
precede obesity [42]. Perivascular adipose tissue (PVAT) was 
shown to express NOX and secrete ROS influencing 
hypertension and the metabolic syndrome [32, 38, 43, 44]. The 
stromal vascular fraction (SVF) from which ASCs are 
derived is composed largely by PVAT [13]. Further studies of 
the specific nature of abdominal ASCs may provide 
additional mechanistic indications to the genetic signature 
that promote ASCs phenotype and possibly ROS 
accumulation in obese individuals.  
Does the epigenetic state of MSCs dictate their tissue 
specific traits?  
The underlying basis for tissue specific cell phenotypes is 
most likely epigenetic. It was previously shown that induced 
pluripotent stem cells (iPSCs) carry an epigenetic memory 
from their tissue of origin [45]. It is therefore possible that the 
distinction between MSCs that are derived from different 
tissues could be made based on their epigenetic profile. 
Bisulfite sequencing revealed, however, that DNA 
methylation of lineage specific promoters of MSCs derived 
from different tissues is similar [46]. In contrast, our previous 
findings showed that H4K20me1 modulation is a key event 
in the reprogramming of BM MSCs [31]. Thus, it is possible 
that although tissue specific MSCs display similar DNA 
methylation marks they can still display an epigenetic profile 
with distinct features. To uncover this possibility, further 
studies comparing different histone marks between tissue 
specific MSCs are needed. 
Conclusions 
Although all MSCs are multipotent and plastic adherent, 
accumulating data now suggest that tissue specific MSCs 
differ in basic and fundamental properties that may have a 
critical effect on their clinical efficacy. This understanding 
should be harnessed to the development of distinct 
propagation and treatment protocols for MSCs that are 
isolated from different tissues. Gaining deeper understanding 
of the tissue specific traits of MSCs and their molecular 
signatures will not only assist in designing such protocols but 
may also shed light on the physiological properties of MSC 
progenitors in situ. 
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